Personalis (NASDAQ:PSNL) Shares Down 8.6% – Here’s What Happened

Personalis, Inc. (NASDAQ:PSNL) dropped 8.6% during mid-day trading on Thursday . The company traded as low as $8.69 and last traded at $8.5420. Approximately 219,692 shares changed hands during mid-day trading, a decline of 77% from the average daily volume of 941,280 shares. The stock had previously closed at $9.35.

Analyst Ratings Changes

Several research analysts recently commented on the stock. Wall Street Zen cut shares of Personalis from a “hold” rating to a “sell” rating in a report on Saturday, January 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Personalis in a research report on Wednesday, October 8th. Needham & Company LLC increased their price objective on shares of Personalis from $7.00 to $10.00 and gave the stock a “buy” rating in a research note on Wednesday, November 5th. BTIG Research reaffirmed a “buy” rating and issued a $12.00 target price on shares of Personalis in a research report on Friday. Finally, HC Wainwright upped their target price on Personalis from $8.50 to $10.00 and gave the stock a “buy” rating in a report on Thursday, November 6th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Personalis presently has an average rating of “Moderate Buy” and an average target price of $10.57.

Personalis Stock Performance

The company has a market cap of $719.28 million, a P/E ratio of -9.20 and a beta of 1.96. The business’s 50-day moving average price is $8.72 and its 200 day moving average price is $7.26.

Personalis (NASDAQ:PSNL) last issued its earnings results on Tuesday, November 4th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.04. Personalis had a negative net margin of 106.92% and a negative return on equity of 38.25%. The company had revenue of $14.50 million for the quarter, compared to analysts’ expectations of $13.31 million. Equities research analysts forecast that Personalis, Inc. will post -1.4 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Christopher M. Hall sold 29,612 shares of the stock in a transaction on Monday, November 3rd. The stock was sold at an average price of $8.99, for a total value of $266,211.88. Following the sale, the chief executive officer owned 148,486 shares in the company, valued at approximately $1,334,889.14. This represents a 16.63% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Aaron Tachibana sold 103,668 shares of the firm’s stock in a transaction on Tuesday, November 25th. The shares were sold at an average price of $10.78, for a total value of $1,117,541.04. Following the sale, the chief financial officer directly owned 164,458 shares of the company’s stock, valued at $1,772,857.24. This represents a 38.66% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 3.80% of the company’s stock.

Hedge Funds Weigh In On Personalis

Several institutional investors and hedge funds have recently modified their holdings of PSNL. Legal & General Group Plc acquired a new stake in shares of Personalis during the 2nd quarter worth about $30,000. Ameritas Investment Partners Inc. bought a new position in Personalis in the 2nd quarter valued at about $34,000. BNP Paribas Financial Markets lifted its position in Personalis by 406.4% during the second quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock worth $42,000 after acquiring an additional 5,177 shares during the last quarter. Alpha Wealth Funds LLC bought a new stake in shares of Personalis during the second quarter worth approximately $66,000. Finally, Farther Finance Advisors LLC bought a new stake in shares of Personalis during the third quarter worth approximately $66,000. 61.91% of the stock is currently owned by institutional investors and hedge funds.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.